Radiation-Therapy Overview:@0.649614:0.035749:0.914543:0.035749:0.914543:0.019993:0.649614:0.019993:0.011680:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.016722:0.010660:0.012508:0.005792:0.010660:0.003848:0.012508:0.015990
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
23:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
check-lists, quality control and preven-:@0.084242:0.096166:0.475160:0.096166:0.475160:0.080410:0.084242:0.080410:0.012450:0.011738:0.012508:0.012450:0.009660:0.006388:0.003848:0.003848:0.007466:0.006523:0.007466:0.005330:0.013143:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.013143:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.013143:0.013143:0.011738:0.013181:0.013143:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006388
tive maintenance, a dosimetric audit, ac-:@0.084242:0.112729:0.475152:0.112729:0.475152:0.096973:0.084242:0.096973:0.006523:0.003848:0.010660:0.012508:0.005907:0.018049:0.013143:0.003848:0.011738:0.006523:0.012508:0.011738:0.013143:0.011738:0.012450:0.012508:0.005330:0.005907:0.013143:0.005907:0.013181:0.012604:0.007466:0.003848:0.018049:0.012508:0.006523:0.005792:0.003848:0.012450:0.005907:0.013143:0.011699:0.013181:0.003848:0.006523:0.005330:0.005907:0.013143:0.012450:0.006388
creditation,  the minimisation  of  interrup-:@0.084242:0.129291:0.475152:0.129291:0.475152:0.113535:0.084242:0.113535:0.012450:0.005713:0.012508:0.013181:0.003848:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.005161:0.006523:0.011738:0.012508:0.010506:0.018049:0.003848:0.011738:0.003848:0.018049:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005167:0.012604:0.006042:0.005330:0.005163:0.003848:0.011738:0.006523:0.012508:0.005792:0.005792:0.011699:0.013106:0.006388
tions, prospective risk assessment, and the :@0.084242:0.145854:0.480482:0.145854:0.480482:0.130098:0.084242:0.130098:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005523:0.013123:0.005715:0.012604:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005523:0.005792:0.003848:0.007466:0.009660:0.005523:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.018049:0.012508:0.011738:0.006523:0.005330:0.005523:0.013143:0.011738:0.013181:0.005523:0.006523:0.011738:0.012508:0.005330
changing of organisational culture.:@0.084242:0.162417:0.411592:0.162417:0.411592:0.146661:0.084242:0.146661:0.012450:0.011738:0.013143:0.011738:0.012950:0.003848:0.011738:0.012950:0.005330:0.012604:0.006042:0.005330:0.012604:0.005792:0.012950:0.013143:0.011738:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.012450:0.011699:0.003848:0.006523:0.011699:0.005713:0.012508:0.005330
13:@0.411579:0.156805:0.424009:0.156805:0.424009:0.147619:0.411579:0.147619:0.006215:0.006215
CONCLUSION:@0.084242:0.196200:0.239464:0.196200:0.239464:0.176603:0.084242:0.176603:0.018344:0.019756:0.017404:0.018344:0.010348:0.015052:0.012230:0.006585:0.019756:0.017404
The major challenge in radiation therapy :@0.084242:0.215057:0.480505:0.215057:0.480505:0.199301:0.084242:0.199301:0.008005:0.011545:0.012315:0.008852:0.017857:0.012950:0.003714:0.012411:0.005600:0.008852:0.012257:0.011545:0.012950:0.003656:0.003656:0.012315:0.011545:0.012758:0.012315:0.008852:0.003656:0.011545:0.008852:0.005600:0.012950:0.012989:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.008852:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010318:0.005330
is to broaden the current cross-disciplinary :@0.084242:0.231620:0.480457:0.231620:0.480457:0.215864:0.084242:0.215864:0.003656:0.007274:0.006773:0.006331:0.012411:0.006773:0.012931:0.005519:0.012411:0.012950:0.012989:0.012315:0.011545:0.006773:0.006331:0.011545:0.012315:0.006773:0.012257:0.011507:0.005600:0.005521:0.012315:0.011545:0.006331:0.006773:0.012257:0.005521:0.012411:0.007274:0.007274:0.006196:0.012989:0.003656:0.007274:0.012257:0.003656:0.012931:0.003656:0.003656:0.011545:0.012950:0.005600:0.010316:0.005330
team of radiation oncologists, medical :@0.084242:0.248183:0.480486:0.248183:0.480486:0.232427:0.084242:0.232427:0.006331:0.012315:0.012950:0.017857:0.014528:0.012411:0.005850:0.014528:0.005600:0.012950:0.012989:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.014528:0.012411:0.011545:0.012257:0.012411:0.003656:0.012411:0.012758:0.003656:0.007274:0.006331:0.007274:0.005138:0.014528:0.017857:0.012315:0.012989:0.003656:0.012257:0.012950:0.003852:0.005330
physicists and radiation biologists to in-:@0.084242:0.264746:0.475113:0.264746:0.475113:0.248990:0.084242:0.248990:0.012931:0.011545:0.010122:0.007274:0.003656:0.012257:0.003656:0.007274:0.006331:0.007274:0.013258:0.012950:0.011545:0.012989:0.013258:0.005600:0.012950:0.012989:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.013258:0.012931:0.003656:0.012411:0.003656:0.012411:0.012758:0.003656:0.007274:0.006331:0.007274:0.013258:0.006331:0.012411:0.013258:0.003656:0.011545:0.006388
clude engineers and mathematicians in a :@0.084242:0.281309:0.480503:0.281309:0.480503:0.265553:0.084242:0.265553:0.012257:0.003656:0.011507:0.012989:0.012315:0.006716:0.012315:0.011545:0.012758:0.003656:0.011545:0.012315:0.012315:0.005600:0.007274:0.006716:0.012950:0.011545:0.012989:0.006716:0.017857:0.012950:0.006331:0.011545:0.012315:0.017857:0.012950:0.006331:0.003656:0.012257:0.003656:0.012950:0.011545:0.007274:0.006716:0.003656:0.011545:0.006716:0.013144:0.005330
systems-science/biology  approach.  New :@0.084242:0.297872:0.480482:0.297872:0.480482:0.282116:0.084242:0.282116:0.007274:0.010122:0.007274:0.006331:0.012315:0.017857:0.007274:0.006196:0.007274:0.012257:0.003656:0.012315:0.011545:0.012257:0.012315:0.008217:0.012931:0.003656:0.012411:0.003656:0.012411:0.012758:0.010122:0.005330:0.008419:0.012950:0.012931:0.012931:0.005521:0.012411:0.012950:0.012257:0.011545:0.005138:0.005330:0.008419:0.014047:0.012315:0.015992:0.005330
technologies may reduce costs, as will the :@0.084242:0.314435:0.480488:0.314435:0.480488:0.298679:0.084242:0.298679:0.006331:0.012315:0.012257:0.011545:0.011545:0.012411:0.003656:0.012411:0.012758:0.003656:0.012315:0.007274:0.006100:0.017857:0.012950:0.010122:0.006090:0.005521:0.012315:0.012989:0.011507:0.012257:0.012315:0.006090:0.012257:0.012411:0.007274:0.006331:0.007274:0.005138:0.006090:0.012950:0.007274:0.006090:0.015798:0.003656:0.003656:0.003656:0.006090:0.006331:0.011545:0.012506:0.005330
development of efficiencies (i.e., class solu-:@0.084242:0.330998:0.475150:0.330998:0.475150:0.315242:0.084242:0.315242:0.012989:0.012315:0.010468:0.012315:0.003656:0.012411:0.012931:0.017857:0.012315:0.011545:0.006331:0.004391:0.012411:0.005850:0.004391:0.012315:0.005850:0.004589:0.004589:0.012257:0.003656:0.012315:0.011545:0.012257:0.003656:0.012315:0.007274:0.004391:0.006908:0.003656:0.005138:0.012315:0.005138:0.005138:0.004391:0.012257:0.003656:0.012950:0.007274:0.007274:0.004389:0.007274:0.012411:0.003656:0.011507:0.006388
tions for planning, better plans that reduce :@0.084242:0.347560:0.480513:0.347560:0.480513:0.331805:0.084242:0.331805:0.006331:0.003656:0.012411:0.011545:0.007274:0.005282:0.005850:0.012411:0.005600:0.005292:0.012931:0.003656:0.012950:0.011545:0.011545:0.003656:0.011545:0.012758:0.005138:0.005282:0.012931:0.012315:0.006331:0.006331:0.012315:0.005600:0.005282:0.012931:0.003656:0.012950:0.011545:0.007274:0.005282:0.006331:0.011545:0.012950:0.006331:0.005292:0.005519:0.012315:0.012989:0.011507:0.012257:0.012504:0.005330
treatment time and improve scheduling). :@0.084242:0.364123:0.480472:0.364123:0.480472:0.348367:0.084242:0.348367:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.008717:0.006331:0.003656:0.017857:0.012315:0.008717:0.012950:0.011545:0.012989:0.008717:0.003656:0.017857:0.012931:0.005521:0.012411:0.010468:0.012315:0.008717:0.007274:0.012257:0.011545:0.012315:0.012989:0.011507:0.003656:0.003656:0.011545:0.012758:0.006908:0.005326:0.005330
Proton therapy with superior dose distri-:@0.084242:0.380686:0.475188:0.380686:0.475188:0.364930:0.084242:0.364930:0.011199:0.005521:0.012411:0.006331:0.012411:0.011545:0.012046:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.012046:0.015798:0.003656:0.006331:0.011545:0.012046:0.007274:0.011507:0.012931:0.012315:0.005600:0.003656:0.012411:0.005600:0.012046:0.012989:0.012411:0.007274:0.012315:0.012046:0.012989:0.003656:0.007274:0.006331:0.005600:0.003656:0.006388
bution  has  an  advantage  over  photons,  :@0.084242:0.397249:0.480482:0.397249:0.480482:0.381493:0.084242:0.381493:0.012931:0.011507:0.006331:0.003656:0.012411:0.011545:0.005330:0.004761:0.011545:0.012950:0.007274:0.005330:0.004761:0.012950:0.011545:0.005330:0.004761:0.012950:0.012989:0.010468:0.012950:0.011545:0.006331:0.012950:0.012758:0.012315:0.005330:0.004762:0.012411:0.010468:0.012315:0.005600:0.005330:0.004761:0.012931:0.011545:0.012411:0.006331:0.012411:0.011545:0.007274:0.005328:0.000000:0.005330
although the cost at 2.4 times that of IMRT is :@0.084242:0.413812:0.480463:0.413812:0.480463:0.398056:0.084242:0.398056:0.012950:0.003656:0.006331:0.011545:0.012411:0.011507:0.012758:0.011545:0.004349:0.006331:0.011545:0.012315:0.004349:0.012257:0.012411:0.007274:0.006331:0.004349:0.012950:0.006331:0.004349:0.010468:0.005138:0.010468:0.004349:0.006331:0.003656:0.017857:0.012315:0.007274:0.004349:0.006331:0.011545:0.012950:0.006331:0.004349:0.012411:0.005850:0.004349:0.004156:0.017491:0.011599:0.008005:0.004349:0.003656:0.007470:0.005330
prohibitive. Expected improvements in tar-:@0.084242:0.430375:0.475148:0.430375:0.475148:0.414619:0.084242:0.414619:0.012931:0.005521:0.012411:0.011545:0.003656:0.012931:0.003656:0.006331:0.003656:0.010468:0.012315:0.005138:0.006273:0.010122:0.009044:0.012931:0.012315:0.012257:0.006331:0.012315:0.012989:0.006273:0.003656:0.017857:0.012931:0.005521:0.012411:0.010468:0.012315:0.017857:0.012315:0.011545:0.006331:0.007274:0.006273:0.003656:0.011545:0.006273:0.006331:0.012950:0.005600:0.006388
get localisation with a higher dose to the :@0.084242:0.446938:0.480499:0.446938:0.480499:0.431182:0.084242:0.431182:0.012758:0.012315:0.006331:0.007851:0.003656:0.012411:0.012257:0.012950:0.003656:0.003656:0.007274:0.012950:0.006331:0.003656:0.012411:0.011545:0.007851:0.015798:0.003656:0.006331:0.011545:0.007851:0.012950:0.007851:0.011545:0.003656:0.012758:0.011545:0.012315:0.005600:0.007851:0.012989:0.012411:0.007274:0.012315:0.007851:0.006331:0.012411:0.007851:0.006331:0.011545:0.012506:0.005330
target  and  normal-tissue-dose  reduction :@0.084242:0.463501:0.480492:0.463501:0.480492:0.447745:0.084242:0.447745:0.006331:0.012950:0.005613:0.012758:0.012315:0.006331:0.005330:0.007379:0.012950:0.011545:0.012989:0.005330:0.007378:0.011545:0.012411:0.006131:0.017857:0.012950:0.003656:0.006196:0.006331:0.003656:0.007274:0.007274:0.011507:0.012315:0.006196:0.012989:0.012411:0.007274:0.012315:0.005330:0.007379:0.005521:0.012315:0.012989:0.011507:0.012257:0.006331:0.003656:0.012411:0.011736:0.005330
will result in greater tumour control and a :@0.084242:0.480064:0.480499:0.480064:0.480499:0.464308:0.084242:0.464308:0.015798:0.003656:0.003656:0.003656:0.007799:0.005521:0.012315:0.007274:0.011507:0.003656:0.006331:0.007801:0.003656:0.011545:0.007799:0.012758:0.005519:0.012315:0.012950:0.006331:0.012315:0.005600:0.007799:0.006331:0.011507:0.017857:0.012411:0.011507:0.005600:0.007799:0.012257:0.012411:0.011545:0.006331:0.005521:0.012411:0.003656:0.007799:0.012950:0.011545:0.012989:0.007799:0.013144:0.005330
significant reduction in adverse post-treat-:@0.084242:0.496627:0.475160:0.496627:0.475160:0.480871:0.084242:0.480871:0.007274:0.003656:0.012758:0.011545:0.003656:0.004589:0.004589:0.012257:0.012950:0.011545:0.006331:0.006787:0.005519:0.012315:0.012989:0.011507:0.012257:0.006331:0.003656:0.012411:0.011545:0.006787:0.003656:0.011545:0.006787:0.012950:0.012989:0.010468:0.012315:0.005600:0.007274:0.012315:0.006787:0.012931:0.012411:0.007274:0.006331:0.006196:0.006331:0.005519:0.012315:0.012950:0.006331:0.006388
ment morbidity. Trends point to combined :@0.084242:0.513190:0.480536:0.513190:0.480536:0.497434:0.084242:0.497434:0.017857:0.012315:0.011545:0.006331:0.006677:0.017857:0.012411:0.005600:0.012931:0.003656:0.012989:0.003656:0.006331:0.010122:0.005138:0.006677:0.007426:0.005521:0.012315:0.011545:0.012989:0.007274:0.006677:0.012931:0.012411:0.003656:0.011545:0.006331:0.006677:0.006331:0.012411:0.006677:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012315:0.013181:0.005330
(RT CT)  modality  treatment,  extra-cranial :@0.084242:0.529753:0.480497:0.529783:0.480497:0.514027:0.084242:0.513997:0.006908:0.011599:0.008197:0.012478:0.015452:0.008005:0.006908:0.005330:0.004512:0.017857:0.012411:0.012989:0.012950:0.003656:0.003656:0.006331:0.010122:0.005330:0.004510:0.006331:0.005521:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005138:0.005330:0.004512:0.012315:0.009044:0.006331:0.005600:0.012950:0.006196:0.012257:0.005600:0.012950:0.011545:0.003656:0.012950:0.003852:0.231702
+:@0.110753:0.531707:0.123665:0.531707:0.123665:0.513501:0.110753:0.513501:0.012912
stereotactic radiation, hypo-fractionation :@0.084248:0.546346:0.480501:0.546346:0.480501:0.530590:0.084248:0.530590:0.007274:0.006331:0.012315:0.005521:0.012315:0.012411:0.006331:0.012950:0.012257:0.006331:0.003656:0.012257:0.011430:0.005600:0.012950:0.012989:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.005138:0.011430:0.011545:0.010122:0.012931:0.012411:0.006196:0.005850:0.005600:0.012950:0.012257:0.006331:0.003656:0.012411:0.011545:0.012950:0.006331:0.003656:0.012411:0.011734:0.005330
protocols and mid-therapy redesign of the :@0.084248:0.562909:0.480537:0.562909:0.480537:0.547153:0.084248:0.547153:0.012931:0.005521:0.012411:0.006331:0.012411:0.012257:0.012411:0.003656:0.007274:0.005753:0.012950:0.011545:0.012989:0.005753:0.017857:0.003656:0.012989:0.006196:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005753:0.005519:0.012315:0.012989:0.012315:0.007274:0.003656:0.012758:0.011545:0.005753:0.012411:0.005850:0.005753:0.006331:0.011545:0.012506:0.005330
radiation  dose  (adaptive  radiation  ther-:@0.084248:0.579472:0.475157:0.579472:0.475157:0.563716:0.084248:0.563716:0.005600:0.012950:0.012989:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.005330:0.006687:0.012989:0.012411:0.007274:0.012315:0.005330:0.006687:0.006908:0.012950:0.012989:0.012950:0.012931:0.006331:0.003656:0.010468:0.012315:0.005330:0.006687:0.005600:0.012950:0.012989:0.003656:0.012950:0.006331:0.003656:0.012411:0.011545:0.005330:0.006687:0.006331:0.011545:0.012315:0.005600:0.006388
apy). Use of functional imaging for target :@0.084248:0.596035:0.480501:0.596035:0.480501:0.580279:0.084248:0.580279:0.012950:0.012931:0.010122:0.006908:0.005138:0.007562:0.012411:0.007274:0.012315:0.007562:0.012411:0.005850:0.007562:0.005850:0.011507:0.011545:0.012257:0.006331:0.003656:0.012411:0.011545:0.012950:0.003656:0.007562:0.003656:0.017857:0.012950:0.012758:0.003656:0.011545:0.012758:0.007562:0.005850:0.012411:0.005600:0.007562:0.006331:0.012950:0.005615:0.012758:0.012315:0.006521:0.005330
definition  in  addition  to  the  consolidated :@0.084248:0.612598:0.480507:0.612598:0.480507:0.596842:0.084248:0.596842:0.012989:0.012315:0.004589:0.004589:0.011545:0.003656:0.006331:0.003656:0.012411:0.011545:0.005330:0.003802:0.003656:0.011545:0.005330:0.003802:0.012950:0.012989:0.012989:0.003656:0.006331:0.003656:0.012411:0.011545:0.005330:0.003802:0.006331:0.012411:0.005330:0.003802:0.006331:0.011545:0.012315:0.005330:0.003802:0.012257:0.012411:0.011545:0.007274:0.012411:0.003656:0.003656:0.012989:0.012950:0.006331:0.012315:0.013181:0.005330
quality assurance programme will play an :@0.084248:0.629015:0.480445:0.629015:0.480445:0.613259:0.084248:0.613259:0.012931:0.011507:0.012950:0.003656:0.003656:0.006331:0.010122:0.006947:0.012950:0.007274:0.007274:0.011507:0.005600:0.012950:0.011545:0.012257:0.012315:0.006947:0.012931:0.005521:0.012411:0.012758:0.005600:0.012950:0.017857:0.017857:0.012315:0.006947:0.015798:0.003656:0.003656:0.003656:0.006947:0.012931:0.003656:0.012950:0.010122:0.006947:0.012950:0.011736:0.005330
important role in the future.:@0.084248:0.645432:0.332063:0.645432:0.332063:0.629676:0.084248:0.629676:0.003656:0.017857:0.012931:0.012411:0.005600:0.006331:0.012950:0.011545:0.006331:0.005138:0.005519:0.012411:0.003656:0.012315:0.005138:0.003656:0.011545:0.005138:0.006331:0.011545:0.012315:0.005138:0.005850:0.011507:0.006331:0.011507:0.005519:0.012315:0.005330
REFERENCES:@0.084248:0.675330:0.195084:0.675330:0.195084:0.659297:0.084248:0.659297:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1.:@0.084242:0.692312:0.098456:0.692312:0.098456:0.678307:0.084242:0.678307:0.009476:0.004738
  American  Cancer  Society – cancer  facts:@0.120589:0.692312:0.475156:0.692312:0.475156:0.678307:0.120589:0.678307:0.004738:-0.004738:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.004738:0.003199:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003204:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.007954:0.008552:0.007954:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003204:0.005371:0.011682:0.011067:0.005798:0.006636
and figures 2017.:@0.120589:0.706670:0.259601:0.706670:0.259601:0.692665:0.120589:0.692665:0.011682:0.010434:0.011716:0.004738:0.004165:0.004165:0.011511:0.010399:0.005068:0.011118:0.006636:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
2.:@0.084242:0.721028:0.098456:0.721028:0.098456:0.707023:0.084242:0.707023:0.009476:0.004738
  Ferlay J,  Soerjomataram  I,  Dikshit R, :@0.120589:0.721028:0.428132:0.721028:0.428132:0.707023:0.120589:0.707023:0.004738:-0.004738:0.008296:0.011118:0.005148:0.003421:0.011682:0.009168:0.007509:0.008244:0.004738:0.004738:0.002754:0.008518:0.011203:0.011118:0.005148:0.003472:0.011203:0.016044:0.011682:0.005798:0.011682:0.005148:0.011682:0.016044:0.004738:0.002752:0.003866:0.004738:0.004738:0.002762:0.012726:0.003421:0.008586:0.006636:0.010434:0.003421:0.005798:0.007509:0.010382:0.004738:0.004738
et  al:@0.430896:0.721028:0.470414:0.721028:0.470414:0.707023:0.430896:0.707023:0.011118:0.005798:0.004738:0.002761:0.011682:0.003421
.:@0.470414:0.721028:0.475152:0.721028:0.475152:0.707023:0.470414:0.707023:0.004738
Cancer  incidence  and  mortality  world-:@0.120589:0.735386:0.475154:0.735386:0.475154:0.721381:0.120589:0.721381:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.007887:0.003421:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.004738:0.007892:0.011682:0.010434:0.011716:0.004738:0.007894:0.016044:0.011203:0.005148:0.005798:0.011682:0.003421:0.003421:0.005798:0.009168:0.004738:0.007894:0.014214:0.011203:0.005148:0.003421:0.011716:0.005679
wide: sources, methods and major patterns :@0.120589:0.749744:0.479912:0.749744:0.479912:0.735739:0.120589:0.735739:0.014214:0.003421:0.011716:0.011118:0.004738:0.003917:0.006636:0.011203:0.010399:0.005029:0.011067:0.011118:0.006636:0.004738:0.003917:0.016044:0.011118:0.005798:0.010434:0.011203:0.011716:0.006636:0.003917:0.011682:0.010434:0.011716:0.003917:0.016044:0.011682:0.003472:0.011203:0.005148:0.003917:0.011665:0.011682:0.005798:0.005798:0.011118:0.005502:0.010434:0.006636:0.004738
in GLOBOCAN 2012.:@0.559983:0.094730:0.724961:0.094730:0.724961:0.080725:0.559983:0.080725:0.003421:0.010434:0.003455:0.014915:0.007902:0.014864:0.009818:0.014864:0.013906:0.012657:0.012657:0.003445:0.009476:0.009476:0.009476:0.009476:0.004738
 Int J Cancer. :@0.724961:0.094730:0.836499:0.094730:0.836499:0.080725:0.724961:0.080725:0.003455:0.003866:0.010434:0.005798:0.003455:0.008244:0.003455:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738
136,E359–:@0.835216:0.094730:0.914529:0.094730:0.914529:0.080725:0.835216:0.080725:0.009476:0.009476:0.009476:0.004738:0.009168:0.009476:0.009476:0.009476:0.008552
E386(2015) VC 2014 UICC.:@0.559983:0.108853:0.773753:0.108853:0.773753:0.094848:0.559983:0.094848:0.009168:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.012007:0.013906:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.011203:0.003866:0.013906:0.013906:0.004738
3.:@0.523636:0.122976:0.537850:0.122976:0.537850:0.108970:0.523636:0.108970:0.009476:0.004738
  South African Cancer Registry Report. 2013::@0.559983:0.122976:0.914536:0.122976:0.914536:0.108970:0.559983:0.108970:0.004738:-0.004738:0.008518:0.011203:0.010399:0.005798:0.010434:0.003831:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.003838:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.003838:0.010382:0.011118:0.011511:0.003421:0.006636:0.005798:0.005148:0.009168:0.003848:0.010382:0.011118:0.011665:0.011203:0.005148:0.005798:0.004738:0.003831:0.009476:0.009476:0.009476:0.009476:0.004738
1-2. Http://www.cansa.org.za.  Accessed:@0.559983:0.137099:0.914531:0.137099:0.914531:0.123093:0.559983:0.123093:0.009476:0.005679:0.009476:0.004738:0.014316:0.011682:0.005798:0.005798:0.011665:0.004738:0.007475:0.007475:0.014214:0.014214:0.014214:0.004738:0.011067:0.011682:0.010434:0.006636:0.011682:0.004738:0.011203:0.005148:0.011511:0.004738:0.007269:0.011682:0.004738:0.004738:0.009570:0.012657:0.011067:0.011067:0.011118:0.006636:0.006636:0.011118:0.011716
Mar 30, 2018.:@0.559983:0.151221:0.668339:0.151221:0.668339:0.137216:0.559983:0.137216:0.015719:0.011682:0.005148:0.004738:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
4.:@0.523636:0.165344:0.537850:0.165344:0.537850:0.151339:0.523636:0.151339:0.009476:0.004738
  Kinsella TJ. Radiation oncology: today and:@0.559983:0.165344:0.914548:0.165344:0.914548:0.151339:0.559983:0.151339:0.004738:-0.004738:0.010109:0.003421:0.010434:0.006636:0.011118:0.003421:0.003421:0.011682:0.005405:0.007286:0.008244:0.004738:0.005388:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005396:0.011203:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.005381:0.005798:0.011203:0.011716:0.011682:0.009168:0.005395:0.011682:0.010434:0.011716
tomorrow. :@0.559983:0.179467:0.649338:0.179467:0.649338:0.165462:0.559983:0.165462:0.005798:0.011203:0.016044:0.011203:0.005148:0.005065:0.011203:0.014214:0.004738:0.004738
Front Oncol.:@0.649338:0.179467:0.750681:0.179467:0.750681:0.165462:0.649338:0.165462:0.008296:0.005148:0.011203:0.010434:0.005798:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2011;1:1-2.:@0.750662:0.179467:0.841623:0.179467:0.841623:0.165462:0.750662:0.165462:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.005679:0.009476:0.004738
5.:@0.523653:0.193590:0.537867:0.193590:0.537867:0.179585:0.523653:0.179585:0.009476:0.004738
  Connell PP, Hellman S. Advances in radio- :@0.560000:0.193590:0.919294:0.193590:0.919294:0.179585:0.560000:0.179585:0.004738:-0.004738:0.013906:0.011203:0.010434:0.010434:0.011118:0.003421:0.003421:0.006534:0.010126:0.008005:0.004738:0.006534:0.011682:0.011118:0.003421:0.003421:0.016044:0.011682:0.010434:0.006534:0.008518:0.004738:0.006534:0.012657:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.006636:0.006534:0.003421:0.010434:0.006534:0.005148:0.011682:0.011716:0.003421:0.011203:0.005679:0.004738
therapy and implications for the next cen-:@0.559983:0.207713:0.914568:0.207713:0.914568:0.193708:0.559983:0.193708:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005764:0.011682:0.010434:0.011716:0.005764:0.003421:0.016044:0.011665:0.003421:0.003421:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.005776:0.005371:0.011203:0.005148:0.005764:0.005798:0.010434:0.011118:0.005764:0.010434:0.011118:0.008210:0.005798:0.005764:0.011067:0.011118:0.010434:0.005679
tury:  a historical perspective. :@0.559983:0.221836:0.811990:0.221836:0.811990:0.207830:0.559983:0.207830:0.005798:0.010399:0.005148:0.009168:0.004738:0.004738:0.003635:0.011682:0.008381:0.010434:0.003421:0.006636:0.005798:0.011203:0.005148:0.003421:0.011067:0.011682:0.003421:0.008381:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.004738
Cancer Re-:@0.815633:0.221836:0.914548:0.221836:0.914548:0.207830:0.815633:0.207830:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.008381:0.010382:0.011118:0.005679
search:@0.559983:0.235959:0.616068:0.235959:0.616068:0.221953:0.559983:0.221953:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434
. 2009;69(2):383-392.:@0.616068:0.235959:0.781245:0.235959:0.781245:0.221953:0.616068:0.221953:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
6. :@0.523636:0.250082:0.542605:0.250082:0.542605:0.236076:0.523636:0.236076:0.009476:0.004755:0.573294
  Gupta  S,:@0.560000:0.250082:0.635853:0.250082:0.635853:0.236076:0.560000:0.236076:0.004738:-0.004738:0.014915:0.010399:0.011665:0.005798:0.011682:0.004738:0.003399:0.008518:0.004738
 et  al.:@0.635853:0.250082:0.688885:0.250082:0.688885:0.236076:0.635853:0.236076:0.008142:0.011118:0.005798:0.004738:0.003395:0.011682:0.003421:0.004738
 Radiobiological concepts:@0.688885:0.250082:0.914577:0.250082:0.914577:0.236076:0.688885:0.236076:0.008142:0.010382:0.011682:0.011716:0.003421:0.011203:0.011665:0.003421:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.011682:0.003421:0.008142:0.011067:0.011203:0.010434:0.011067:0.011118:0.011665:0.005798:0.006636
of  high  dose  hypo-fractionated  radiation:@0.560000:0.264204:0.914565:0.264204:0.914565:0.250199:0.560000:0.250199:0.011203:0.005371:0.004738:0.003867:0.010434:0.003421:0.011511:0.010434:0.004738:0.003871:0.011716:0.011203:0.006636:0.011118:0.004738:0.003871:0.010434:0.009168:0.011665:0.011203:0.005679:0.005371:0.005148:0.011682:0.011067:0.005798:0.003421:0.011203:0.010434:0.011682:0.005798:0.011118:0.011716:0.004738:0.003862:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434
therapy. In Pollack A, Ahmed MM, editors.:@0.560000:0.278327:0.914591:0.278327:0.914591:0.264322:0.560000:0.264322:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.005952:0.003866:0.010434:0.005952:0.010126:0.011203:0.003421:0.003421:0.011682:0.011067:0.008586:0.005952:0.012657:0.004738:0.005952:0.012657:0.010434:0.016044:0.011118:0.011716:0.005952:0.015719:0.015719:0.004738:0.005952:0.011118:0.011716:0.003421:0.005798:0.011203:0.005148:0.006636:0.004738
Hypo-fractionation:  scientific  concepts:@0.560000:0.292156:0.914568:0.292156:0.914568:0.278151:0.560000:0.278151:0.011682:0.009168:0.011665:0.011203:0.005679:0.005371:0.005148:0.011682:0.011067:0.005798:0.003421:0.011203:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738:0.017002:0.006636:0.011067:0.003421:0.011118:0.010434:0.005798:0.003421:0.004165:0.004165:0.011067:0.004738:0.017014:0.011067:0.011203:0.010434:0.011067:0.011118:0.011665:0.005798:0.006636
and clinical experiences.:@0.560000:0.305985:0.765297:0.305985:0.765297:0.291980:0.560000:0.291980:0.011682:0.010434:0.011716:0.003866:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.003876:0.011118:0.008210:0.011665:0.011118:0.005148:0.003421:0.011118:0.010434:0.011067:0.011118:0.006636:0.004738
 Ellicott City:  Lumi-:@0.765297:0.305985:0.914533:0.305985:0.914533:0.291980:0.765297:0.291980:0.003866:0.009168:0.003421:0.003421:0.003421:0.011067:0.011203:0.005798:0.005798:0.003866:0.013906:0.003421:0.005798:0.009168:0.004738:0.003866:0.003866:0.007902:0.010399:0.016044:0.003421:0.005679
Text Publishing; 2011;2:19-38.:@0.560000:0.319814:0.792431:0.319814:0.792431:0.305809:0.560000:0.305809:0.006448:0.011118:0.008210:0.005798:0.004738:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.003421:0.010434:0.011511:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
7.:@0.523653:0.333643:0.537867:0.333643:0.537867:0.319638:0.523653:0.319638:0.009476:0.004738
  Gambhir SS, Czernin J, Schwimmer J,:@0.560000:0.333643:0.866767:0.333643:0.866767:0.319638:0.560000:0.319638:0.004738:-0.004738:0.014915:0.011682:0.016044:0.011665:0.010434:0.003421:0.005148:0.005525:0.008518:0.008518:0.004738:0.005525:0.013906:0.007269:0.011118:0.005508:0.010434:0.003421:0.010434:0.005525:0.008244:0.004738:0.005525:0.008518:0.011067:0.010434:0.014214:0.003421:0.016044:0.016044:0.011118:0.005148:0.005525:0.008244:0.004738
 et al.:@0.866767:0.333643:0.914574:0.333643:0.914574:0.319638:0.866767:0.319638:0.005525:0.011118:0.005798:0.005525:0.011682:0.003421:0.004738
A tabulated summary of the FDG PET litera-:@0.560000:0.347472:0.914539:0.347472:0.914539:0.333466:0.560000:0.333466:0.012657:0.004396:0.005798:0.011682:0.011665:0.010399:0.003421:0.011682:0.005798:0.011118:0.011716:0.004396:0.006636:0.010399:0.016044:0.016044:0.011682:0.005148:0.009168:0.004396:0.011203:0.005371:0.004396:0.005798:0.010434:0.011118:0.004396:0.008296:0.012726:0.014915:0.004396:0.010126:0.009168:0.007286:0.004396:0.003421:0.003421:0.005798:0.011118:0.005148:0.011682:0.005679
ture. :@0.560000:0.361301:0.601865:0.361301:0.601865:0.347295:0.560000:0.347295:0.005798:0.010399:0.005073:0.011118:0.004738:0.004738
J Nucl Med. :@0.601865:0.361301:0.705158:0.361301:0.705158:0.347295:0.601865:0.347295:0.008244:0.004738:0.012657:0.010399:0.011067:0.003421:0.004738:0.015719:0.011118:0.011716:0.004738:0.004738
2001;42:1s-93s.:@0.705131:0.361301:0.823578:0.361301:0.823578:0.347295:0.705131:0.347295:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.006636:0.005679:0.009476:0.009476:0.006636:0.004738
8.:@0.523653:0.375129:0.537867:0.375129:0.537867:0.361124:0.523653:0.361124:0.009476:0.004738
  Camphausen KA, Lawrence RC. Principles:@0.560000:0.375129:0.914556:0.375129:0.914556:0.361124:0.560000:0.361124:0.004738:-0.004738:0.013906:0.011682:0.016044:0.011665:0.010434:0.011682:0.010399:0.006636:0.011118:0.010434:0.006243:0.010109:0.012657:0.004738:0.006226:0.007902:0.011682:0.014214:0.005080:0.011118:0.010434:0.011067:0.011118:0.006243:0.010382:0.013906:0.004738:0.006243:0.010126:0.005148:0.003421:0.010434:0.011067:0.003421:0.011665:0.003421:0.011118:0.006636
of Radiation Therapy. In Pazdur R, Wagman :@0.560000:0.388958:0.919286:0.388958:0.919286:0.374953:0.560000:0.374953:0.011203:0.005371:0.004054:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.004054:0.007286:0.010434:0.011118:0.005136:0.011682:0.011665:0.009168:0.004738:0.004054:0.003866:0.010434:0.004054:0.010126:0.011682:0.007269:0.011716:0.010399:0.005148:0.004054:0.010382:0.004738:0.004054:0.015568:0.011682:0.011511:0.016044:0.011682:0.010434:0.004738
LD, Camphausen KA,  Hoskins WJ, editors.:@0.560000:0.402787:0.914577:0.402787:0.914577:0.388782:0.560000:0.388782:0.007902:0.012726:0.004738:0.007988:0.013906:0.011682:0.016044:0.011665:0.010434:0.011682:0.010399:0.006636:0.011118:0.010434:0.007988:0.010109:0.012657:0.004738:0.004738:0.003236:0.011682:0.011203:0.006636:0.008586:0.003421:0.010434:0.006636:0.007988:0.016420:0.008244:0.004738:0.007988:0.011118:0.011716:0.003421:0.005798:0.011203:0.005148:0.006636:0.004738
Cancer  Management:  a multi-disciplinary:@0.560000:0.416616:0.914544:0.416616:0.914544:0.402611:0.560000:0.402611:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003015:0.015719:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738:0.003010:0.011682:0.007765:0.016044:0.010399:0.003421:0.005798:0.003421:0.005679:0.011716:0.003421:0.006636:0.011067:0.003421:0.011665:0.003421:0.003421:0.010434:0.011682:0.005148:0.009168
approach. :@0.560000:0.430445:0.654023:0.430445:0.654023:0.416440:0.560000:0.416440:0.011682:0.011665:0.011665:0.005148:0.011203:0.011682:0.011067:0.010434:0.004738:0.004738
11th ed. London: Cmp United:@0.657204:0.430445:0.914562:0.430445:0.914562:0.416440:0.657204:0.416440:0.009476:0.009476:0.005798:0.010434:0.007919:0.011118:0.011716:0.004738:0.007919:0.007902:0.011203:0.010434:0.011716:0.011203:0.010422:0.004738:0.007919:0.013906:0.016044:0.011665:0.007919:0.011203:0.010434:0.003421:0.005798:0.011118:0.011716
Business Media; 2008.:@0.560000:0.444274:0.735611:0.444274:0.735611:0.430269:0.560000:0.430269:0.009818:0.010399:0.006636:0.003421:0.010434:0.011118:0.006636:0.006636:0.004738:0.015719:0.011118:0.011716:0.003421:0.011682:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
9.:@0.523653:0.458103:0.537871:0.458103:0.537871:0.444098:0.523653:0.444098:0.009479:0.004738
  Intensity Modulated Radiation Therapy. Irsa.:@0.560000:0.458103:0.914565:0.458103:0.914565:0.444098:0.560000:0.444098:0.004738:-0.004738:0.003523:0.010092:0.005456:0.010776:0.010092:0.006294:0.003079:0.005456:0.008826:0.006346:0.015377:0.010861:0.011374:0.010057:0.003079:0.011340:0.005456:0.010776:0.011374:0.006354:0.010040:0.011340:0.011374:0.003079:0.011340:0.005456:0.003079:0.010861:0.010092:0.006354:0.006944:0.010092:0.010776:0.004806:0.011340:0.011323:0.008826:0.004396:0.006354:0.003523:0.004806:0.006294:0.011340:0.004738
org. http://www.irsa.org/imrt.html.  Accessed:@0.560000:0.471932:0.914587:0.471932:0.914587:0.457926:0.560000:0.457926:0.010861:0.004820:0.011169:0.004396:0.003544:0.010092:0.005456:0.005456:0.011323:0.004396:0.007133:0.007133:0.013872:0.013872:0.013872:0.004396:0.003079:0.004806:0.006294:0.011340:0.004396:0.010861:0.004820:0.011169:0.007133:0.003079:0.015702:0.004806:0.005456:0.004396:0.010092:0.005456:0.015702:0.003079:0.004396:0.003558:0.003558:0.012315:0.010724:0.010724:0.010776:0.006294:0.006294:0.010776:0.011716
Mar 30, 2018.:@0.560000:0.485761:0.668356:0.485761:0.668356:0.471755:0.560000:0.471755:0.015719:0.011682:0.005148:0.004738:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
10.   d’Ambrosio DJ,:@0.523653:0.499589:0.688220:0.499589:0.688220:0.485584:0.523653:0.485584:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.011716:0.006004:0.012657:0.016044:0.011665:0.005078:0.011203:0.006636:0.003421:0.011203:0.006883:0.012726:0.008244:0.064759
 et al.:@0.688220:0.499589:0.738742:0.499589:0.738742:0.485584:0.688220:0.485584:0.006885:0.011118:0.005798:0.006881:0.011682:0.003421:0.004738
 Continuous localisa-:@0.738742:0.499589:0.914555:0.499589:0.914555:0.485584:0.738742:0.485584:0.006893:0.013906:0.011203:0.010434:0.005798:0.003421:0.010434:0.010399:0.011203:0.010399:0.006636:0.006873:0.003421:0.011203:0.011067:0.011682:0.003421:0.003421:0.006636:0.011682:0.005679
tion technologies for radiotherapy delivery::@0.560000:0.513418:0.914574:0.513418:0.914574:0.499413:0.560000:0.499413:0.005798:0.003421:0.011203:0.010434:0.004280:0.005798:0.011118:0.011067:0.010434:0.010434:0.011203:0.003421:0.011203:0.011511:0.003421:0.011118:0.006636:0.004285:0.005371:0.011203:0.005148:0.004274:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004283:0.011716:0.011118:0.003421:0.003421:0.009476:0.011118:0.005148:0.009168:0.004738
Report of the American Society for Radia-:@0.560000:0.527247:0.914565:0.527247:0.914565:0.513242:0.560000:0.513242:0.010382:0.011118:0.011665:0.011203:0.005148:0.005798:0.006190:0.011203:0.005371:0.006200:0.005798:0.010434:0.011118:0.006195:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.006197:0.008518:0.011203:0.011067:0.003421:0.011118:0.005798:0.009168:0.006200:0.005371:0.011203:0.005148:0.006193:0.010382:0.011682:0.011716:0.003421:0.011682:0.005679
tion Oncology Emerging Technology Com-:@0.560000:0.541076:0.914563:0.541076:0.914563:0.527071:0.560000:0.527071:0.005798:0.003421:0.011203:0.010434:0.004909:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004911:0.009168:0.016044:0.011118:0.005159:0.011511:0.003421:0.010434:0.011511:0.004911:0.006448:0.011118:0.011067:0.010434:0.010434:0.011203:0.003421:0.011191:0.011511:0.009168:0.004914:0.013906:0.011203:0.016044:0.005679
mittee. :@0.560000:0.554905:0.622773:0.554905:0.622773:0.540900:0.560000:0.540900:0.016044:0.003421:0.005798:0.005798:0.011118:0.011118:0.004738:0.004738
Pract Radiat Oncol.:@0.622568:0.554905:0.785874:0.554905:0.785874:0.540900:0.622568:0.540900:0.010126:0.005148:0.011682:0.011067:0.005798:0.004534:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.004541:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2012;2:145-150.:@0.785874:0.554905:0.914553:0.554905:0.914553:0.540900:0.785874:0.540900:0.004538:0.009476:0.009476:0.009476:0.009476:0.004738:0.009491:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
11.   Kupelian  P,:@0.523653:0.568734:0.652377:0.568734:0.652377:0.554729:0.523653:0.554729:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010109:0.010399:0.011665:0.011118:0.003421:0.003421:0.011682:0.010434:0.004738:0.002636:0.008017:0.000000
 et al.:@0.652377:0.568734:0.703879:0.568734:0.703879:0.554729:0.652377:0.554729:0.007372:0.011118:0.005798:0.007372:0.011682:0.003421:0.004738
 Multi institutional clinical:@0.703879:0.568734:0.914553:0.568734:0.914553:0.554729:0.703879:0.554729:0.007372:0.015719:0.010399:0.003421:0.005798:0.003421:0.007372:0.003421:0.010434:0.006636:0.005798:0.003421:0.005798:0.010399:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.007372:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421
experience  with the  calypso system in lo-:@0.560000:0.582563:0.914555:0.582563:0.914555:0.568558:0.560000:0.568558:0.011118:0.008210:0.011665:0.011118:0.005148:0.003421:0.011118:0.010434:0.011067:0.011118:0.004738:0.002675:0.014214:0.003421:0.005798:0.010434:0.007423:0.005798:0.010434:0.011118:0.004738:0.002677:0.011067:0.011682:0.003421:0.009168:0.011665:0.006636:0.011203:0.007423:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.007423:0.003421:0.010434:0.007423:0.003421:0.011203:0.005679
calisation and continuous, real time moni-:@0.560000:0.596392:0.914579:0.596392:0.914579:0.582386:0.560000:0.582386:0.011067:0.011682:0.003421:0.003421:0.006636:0.011682:0.005798:0.003421:0.011203:0.010434:0.006363:0.011682:0.010434:0.011716:0.006363:0.011067:0.011203:0.010434:0.005798:0.003421:0.010434:0.010399:0.011203:0.010399:0.006636:0.004738:0.006344:0.005078:0.011118:0.011682:0.003421:0.006363:0.005798:0.003421:0.016044:0.011118:0.006354:0.016044:0.011203:0.010434:0.003421:0.005679
toring of the prostate gland during external :@0.560000:0.610221:0.919298:0.610221:0.919298:0.596215:0.560000:0.596215:0.005798:0.011203:0.005148:0.003421:0.010434:0.011511:0.004238:0.011203:0.005371:0.004245:0.005798:0.010434:0.011118:0.004242:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004245:0.011511:0.003421:0.011682:0.010434:0.011716:0.004249:0.011716:0.010399:0.005148:0.003421:0.010434:0.011511:0.004244:0.011118:0.008210:0.005798:0.011118:0.005499:0.010434:0.011682:0.003421:0.004738
radiotherapy. :@0.560000:0.624049:0.677661:0.624049:0.677661:0.610044:0.560000:0.610044:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Int J Radiat Oncol Biol Phys:@0.679354:0.624049:0.909836:0.624049:0.909836:0.610044:0.679354:0.610044:0.003866:0.010434:0.005798:0.006448:0.008244:0.006448:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.006448:0.014864:0.010434:0.011067:0.011203:0.003421:0.006448:0.009818:0.003421:0.011203:0.003421:0.006448:0.010126:0.010434:0.009168:0.006636
.:@0.909836:0.624049:0.914574:0.624049:0.914574:0.610044:0.909836:0.610044:0.004738
2007;67:1088-1098.:@0.560000:0.637878:0.712554:0.637878:0.712554:0.623873:0.560000:0.623873:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
12.  Dunscombe P. Recommendations for safer:@0.523653:0.651707:0.914558:0.651707:0.914558:0.637702:0.523653:0.637702:0.009476:0.009476:0.004738:0.012657:0.000000:0.012726:0.010399:0.010434:0.006636:0.011067:0.011203:0.016044:0.011665:0.011118:0.004994:0.008569:0.004738:0.005000:0.010382:0.011118:0.011067:0.011203:0.016044:0.016044:0.011118:0.010434:0.011716:0.011674:0.005798:0.003421:0.011203:0.010434:0.006636:0.005000:0.005371:0.011203:0.005148:0.004994:0.006636:0.011682:0.005371:0.011118:-0.382431
radiotherapy: what’s the message? :@0.560000:0.665536:0.869982:0.665536:0.869982:0.651531:0.560000:0.651531:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.008450:0.014214:0.010434:0.011682:0.005798:0.006004:0.006636:0.008450:0.005798:0.010434:0.011118:0.008450:0.016044:0.011118:0.006636:0.006636:0.011682:0.011511:0.011118:0.010109:0.004738
Front:@0.873694:0.665536:0.914574:0.665536:0.914574:0.651531:0.873694:0.651531:0.008296:0.005148:0.011203:0.010434:0.005798
Oncol:@0.560000:0.679365:0.610988:0.679365:0.610988:0.665360:0.560000:0.665360:0.014864:0.010434:0.011067:0.011203:0.003421
. 2012;2:1-6.:@0.610988:0.679365:0.706687:0.679365:0.706687:0.665360:0.610988:0.665360:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.005679:0.009476:0.004738
13.  Clark BG, Brown  RJ,  Ploquin JL.  Patient:@0.523653:0.693488:0.914580:0.693488:0.914580:0.679483:0.523653:0.679483:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.003421:0.011682:0.005148:0.008586:0.011392:0.009818:0.014915:0.004738:0.011392:0.009818:0.005080:0.011203:0.014214:0.010434:0.004738:0.006645:0.010382:0.008244:0.004738:0.004738:0.006643:0.010126:0.003421:0.011203:0.011665:0.010399:0.003421:0.010434:0.011392:0.008244:0.007902:0.004738:0.004738:0.006645:0.010126:0.011682:0.005798:0.003421:0.011118:0.010434:-0.442575
safety improvements in radiation treatment :@0.560000:0.707611:0.919306:0.707611:0.919306:0.693605:0.560000:0.693605:0.006636:0.011682:0.005371:0.011118:0.005798:0.009168:0.003883:0.003421:0.016044:0.011665:0.005078:0.011203:0.009476:0.011118:0.016044:0.011118:0.010434:0.005798:0.006636:0.003883:0.003421:0.010434:0.003883:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.003883:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
through 5 years of incident learning. :@0.560000:0.721734:0.869416:0.721734:0.869416:0.707728:0.560000:0.707728:0.005798:0.010434:0.005073:0.011203:0.010399:0.011511:0.010434:0.006062:0.009476:0.006072:0.009168:0.011118:0.011682:0.005148:0.006636:0.006072:0.011203:0.005371:0.006072:0.003421:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.005798:0.006072:0.003421:0.011118:0.011682:0.005506:0.010434:0.003421:0.010434:0.011511:0.004738:0.004738
Pract:@0.870750:0.721734:0.914572:0.721734:0.914572:0.707728:0.870750:0.707728:0.010126:0.005148:0.011682:0.011067:0.005798
Radiat Oncol. :@0.560000:0.735856:0.679200:0.735856:0.679200:0.721851:0.560000:0.721851:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.004054:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2013 Jul-Sep;3(3):157-63. Doi: :@0.678516:0.735856:0.919277:0.735856:0.919277:0.721851:0.678516:0.721851:0.009476:0.009476:0.009476:0.009476:0.004066:0.008244:0.010399:0.003421:0.005679:0.008518:0.011118:0.011665:0.004738:0.009476:0.006312:0.009476:0.006322:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004066:0.012726:0.011203:0.003421:0.004738:0.004738
10.1016/j. Prro. 2012.08.001.:@0.560000:0.749979:0.782552:0.749979:0.782552:0.735974:0.560000:0.735974:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.003472:0.004738:0.004738:0.010126:0.005148:0.005087:0.011203:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738